Qiagen N.V. Q3 FY2025 earnings call

Thierry thanked teams for strong execution, noting 24th consecutive quarter meeting/exceeding targets; announced acquisition of Parse Biosciences and $500M share repurchase. Growth pillars performing strongly: QIAstat diagnostics grew 11%, QuantiFERON 11% CER, Sample technologies 3% CER, QIAcuity double-digit growth, QIAGEN Digital Insight double-digit growth. Roland discussed financial highlights: core sales up 6% CER, adjusted operating income margin 29.6%, cash generation strong, balance sheet strong; sales by region: Americas 7% CER, EMEA 4% CER, Asia Pacific -2% CER.

Sample technologies: Rose 3% CER, driven by consumables growth (automated kits with double-digit expansion), instrument sales slightly lower but included good placements of QIAsymphony, QIAcube Connect, EZ2 Connect systems. Diagnostic Solutions: Sales rose 4% CER, faster 8% excluding discontinued [NeuMoDx] system; top performers QIAstat and QuantiFERON grew 11% CER, supported by pharma partnerships. PCR and nuclear acid amplification: Stable at constant exchange rates; QIAcuity digital PCR platform grew due to strong consumable demand offsetting lower instrument sales. Genomics and NGS product group: Sales 9% CER, led by QIAGEN Digital Insights bioinformatics business (double-digit growth from current business and Genoox acquisition), with consumables for universal NGS panels also growing.

Raised adjusted EPS target to ~$2.38 CER (increase of $0.10 from initial guidance); net sales growth expected at 4%-5% CER, core portfolio 5%-6% CER growth. Fourth quarter net sales steady, adjusted EPS ~$0.60 CER; currency impact: positive 1% on net sales, adverse $0.02 on EPS for full year.

Impact of U.S. government shutdown on sales (consumables and instruments); tariffs creating ~90 bps margin headwind; competition in markets like QuantiFERON and single-cell analysis.

Q: Talk about Parse acquisition and differentiation.

A: Thierry explained Parse's instrument-free tech, synergies with QIAGEN's portfolio.

Q: Traction for QIAstat new panels.

A: Thierry discussed growth in GI and meningitis panels, renewal opportunities.

Q: Shutdown impact on academic/government.

A: Thierry said shutdown impacts sales but factored into guidance.

Q: Tariffs and margin.

A: Roland and Thierry discussed 90 bps impact, mitigation efforts.

Q: QIAcuity and competitive dynamics.

A: Thierry talked about QIAcuity's growth in biopharma and academic markets, competitive stance.

Q: Parse acquisition EBIT margin and Sample tech growth.

A: Roland discussed Parse's EBIT dilution, Thierry on Sample tech automation and investments.